290 related articles for article (PubMed ID: 37544663)
1. Single-cell sequencing on CD8
Komuro H; Shinohara S; Fukushima Y; Demachi-Okamura A; Muraoka D; Masago K; Matsui T; Sugita Y; Takahashi Y; Nishida R; Takashima C; Ohki T; Shigematsu Y; Watanabe F; Adachi K; Fukuyama T; Hamana H; Kishi H; Miura D; Tanaka Y; Onoue K; Onoguchi K; Yamashita Y; Stratford R; Clancy T; Yamaguchi R; Kuroda H; Doi K; Iwata H; Matsushita H
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37544663
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
Front Immunol; 2020; 11():340. PubMed ID: 32174925
[TBL] [Abstract][Full Text] [Related]
3. Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes.
Levin N; Kim SP; Marquardt CA; Vale NR; Yu Z; Sindiri S; Gartner JJ; Parkhurst M; Krishna S; Lowery FJ; Zacharakis N; Levy L; Prickett TD; Benzine T; Ray S; Masi RV; Gasmi B; Li Y; Islam R; Bera A; Goff SL; Robbins PF; Rosenberg SA
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38816232
[TBL] [Abstract][Full Text] [Related]
4. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.
Hanada KI; Zhao C; Gil-Hoyos R; Gartner JJ; Chow-Parmer C; Lowery FJ; Krishna S; Prickett TD; Kivitz S; Parkhurst MR; Wong N; Rae Z; Kelly MC; Goff SL; Robbins PF; Rosenberg SA; Yang JC
Cancer Cell; 2022 May; 40(5):479-493.e6. PubMed ID: 35452604
[TBL] [Abstract][Full Text] [Related]
5. Cell surface marker-based capture of neoantigen-reactive CD8
Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
[TBL] [Abstract][Full Text] [Related]
6. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
7. Antigen/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application.
Wang X; Dai Z; Lin X; Zou X; Wang R; Tasiheng Y; Yan Y; Ma M; Chen Y; Cheng H; Liu C; Yu X
Cancer Lett; 2024 Apr; 588():216741. PubMed ID: 38395378
[TBL] [Abstract][Full Text] [Related]
8. Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH; Theodoropoulos J; Huuhtanen J; Bhattacharya D; Järvinen P; Tornberg S; Nísen H; Mirtti T; Uski I; Kumari A; Peltonen K; Draghi A; Donia M; Kreutzman A; Mustjoki S
Cancer Res Commun; 2023 Jul; 3(7):1260-1276. PubMed ID: 37484198
[TBL] [Abstract][Full Text] [Related]
9. Functional and molecular characterization of PD1
Lipp JJ; Wang L; Yang H; Yao F; Harrer N; Müller S; Berezowska S; Dorn P; Marti TM; Schmid RA; Hegedüs B; Souabni A; Carotta S; Pearson MA; Sommergruber W; Kocher GJ; Hall SRR
Oncoimmunology; 2022; 11(1):2019466. PubMed ID: 35154905
[TBL] [Abstract][Full Text] [Related]
10. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
[TBL] [Abstract][Full Text] [Related]
11. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
12. TCR repertoire intratumor heterogeneity of CD4
Zhang C; Ding H; Huang H; Palashati H; Miao Y; Xiong H; Lu Z
Int J Cancer; 2019 Feb; 144(4):818-827. PubMed ID: 30151844
[TBL] [Abstract][Full Text] [Related]
13. Functional Heterogeneity of CD4
Oja AE; Piet B; van der Zwan D; Blaauwgeers H; Mensink M; de Kivit S; Borst J; Nolte MA; van Lier RAW; Stark R; Hombrink P
Front Immunol; 2018; 9():2654. PubMed ID: 30505306
[TBL] [Abstract][Full Text] [Related]
14. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
15. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
16. CD8
Lee SW; Choi HY; Lee GW; Kim T; Cho HJ; Oh IJ; Song SY; Yang DH; Cho JH
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593620
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic signatures of circulating neoantigen-reactive CD8
Yossef R; Krishna S; Sindiri S; Lowery FJ; Copeland AR; Gartner JJ; Parkhurst MR; Parikh NB; Hitscherich KJ; Levi ST; Chatani PD; Zacharakis N; Levin N; Vale NR; Nah SK; Dinerman A; Hill VK; Ray S; Bera A; Levy L; Jia L; Kelly MC; Goff SL; Robbins PF; Rosenberg SA
Cancer Cell; 2023 Dec; 41(12):2154-2165.e5. PubMed ID: 38039963
[TBL] [Abstract][Full Text] [Related]
18. Pinpointing the tumor-specific T cells via TCR clusters.
Goncharov MM; Bryushkova EA; Sharaev NI; Skatova VD; Baryshnikova AM; Sharonov GV; Karnaukhov V; Vakhitova MT; Samoylenko IV; Demidov LV; Lukyanov S; Chudakov DM; Serebrovskaya EO
Elife; 2022 Apr; 11():. PubMed ID: 35377314
[TBL] [Abstract][Full Text] [Related]
19. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.
Lowery FJ; Krishna S; Yossef R; Parikh NB; Chatani PD; Zacharakis N; Parkhurst MR; Levin N; Sindiri S; Sachs A; Hitscherich KJ; Yu Z; Vale NR; Lu YC; Zheng Z; Jia L; Gartner JJ; Hill VK; Copeland AR; Nah SK; Masi RV; Gasmi B; Kivitz S; Paria BC; Florentin M; Kim SP; Hanada KI; Li YF; Ngo LT; Ray S; Shindorf ML; Levi ST; Shepherd R; Toy C; Parikh AY; Prickett TD; Kelly MC; Beyer R; Goff SL; Yang JC; Robbins PF; Rosenberg SA
Science; 2022 Feb; 375(6583):877-884. PubMed ID: 35113651
[TBL] [Abstract][Full Text] [Related]
20. Divergent outcomes of anti-PD-L1 treatment coupled with host-intrinsic differences in TCR repertoire and distinct T cell activation states in responding versus non-responding tumors.
John J; Woolaver RA; Popolizio V; Chen SMY; Ge H; Krinsky AL; Vashisht M; Kramer Y; Chen Z; Wang JH
Front Immunol; 2022; 13():992630. PubMed ID: 36330507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]